Aligos Therapeutics, Inc. (ALGS) reported Q4 EPS of ($0.51), $0.03 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $3.54 million versus the consensus estimate of $1.72 million.
Aligos Therapeutics, Inc. (ALGS) reported Q4 EPS of ($0.51), $0.03 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $3.54 million versus the consensus estimate of $1.72 million.